ES2981715T3 - Uso de 2-hidroxibencilamina en el tratamiento y la prevención de la hipertensión pulmonar - Google Patents

Uso de 2-hidroxibencilamina en el tratamiento y la prevención de la hipertensión pulmonar Download PDF

Info

Publication number
ES2981715T3
ES2981715T3 ES17871457T ES17871457T ES2981715T3 ES 2981715 T3 ES2981715 T3 ES 2981715T3 ES 17871457 T ES17871457 T ES 17871457T ES 17871457 T ES17871457 T ES 17871457T ES 2981715 T3 ES2981715 T3 ES 2981715T3
Authority
ES
Spain
Prior art keywords
glutamine
bmpr2
mutant
pah
pulmonary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17871457T
Other languages
English (en)
Spanish (es)
Inventor
Joshua Fessel
L Roberts
James West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Application granted granted Critical
Publication of ES2981715T3 publication Critical patent/ES2981715T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES17871457T 2016-11-15 2017-11-15 Uso de 2-hidroxibencilamina en el tratamiento y la prevención de la hipertensión pulmonar Active ES2981715T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662422486P 2016-11-15 2016-11-15
PCT/US2017/061854 WO2018093936A1 (en) 2016-11-15 2017-11-15 Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension

Publications (1)

Publication Number Publication Date
ES2981715T3 true ES2981715T3 (es) 2024-10-10

Family

ID=62145792

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17871457T Active ES2981715T3 (es) 2016-11-15 2017-11-15 Uso de 2-hidroxibencilamina en el tratamiento y la prevención de la hipertensión pulmonar

Country Status (9)

Country Link
US (2) US20190314302A1 (enExample)
EP (2) EP3541185B1 (enExample)
JP (1) JP7383285B2 (enExample)
CN (1) CN110177463B (enExample)
AU (1) AU2017362328B2 (enExample)
ES (1) ES2981715T3 (enExample)
HU (1) HUE067036T2 (enExample)
PL (1) PL3541185T3 (enExample)
WO (1) WO2018093936A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400103B2 (en) * 2015-12-21 2022-08-02 Vanderbilt University Methods of preventing platelet activation
US20220162240A1 (en) 2019-01-25 2022-05-26 Vanderbilt University Mitochondria-targeted isoketal/isolevuglandin scavengers
EP4097115A4 (en) * 2020-01-27 2024-03-13 Vanderbilt University ANTI-MITOCHONDRIAL ISOKETAL/ISOLEVUGLANDIN SCAVENGERS AND USES THEREOF
JP2023545304A (ja) * 2020-10-13 2023-10-27 ヴァンダービルト ユニバーシティー 腎傷害による腸リンパ管の乱れを予防する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006521349A (ja) 2003-03-27 2006-09-21 メディキュア インコーポレーテッド 狭心症を治療するための組成物
US8822542B2 (en) 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
JP5132109B2 (ja) 2006-09-01 2013-01-30 花王株式会社 一剤式染毛剤組成物
EP3597188A1 (en) * 2006-11-13 2020-01-22 PCB Associates, Inc. An isolated phycobilin for use in a method for prophylaxis or treatment of a medical condition
US8314015B2 (en) 2010-07-14 2012-11-20 Sharp Laboratories Of America, Inc. Silicon surface modification for the electrochemical synthesis of silicon particles in suspension
MX383365B (es) * 2011-07-12 2025-03-13 Univ Vanderbilt Metodos para tratar inflamacion e hipertension con eliminadores de gama-cetoaldehidos.
US20150031068A1 (en) * 2012-03-19 2015-01-29 Lycera Corporation Methods and compositions for detecting immune system activation
WO2015127163A1 (en) * 2014-02-20 2015-08-27 Phd Biosciences ( Formerly Nanometics Llc) Pyridoxamine for the treatment of sickle cell disease, thalassemia and related blood diseases
US20160199463A1 (en) * 2014-12-15 2016-07-14 The Johns Hopkins University Hdac2 defends vascular endothelium from injury

Also Published As

Publication number Publication date
EP3541185A4 (en) 2020-06-24
EP3541185B1 (en) 2024-04-24
EP4385576A2 (en) 2024-06-19
PL3541185T3 (pl) 2024-08-12
WO2018093936A1 (en) 2018-05-24
CN110177463B (zh) 2022-03-08
EP3541185A1 (en) 2019-09-25
AU2017362328B2 (en) 2022-03-31
HUE067036T2 (hu) 2024-09-28
CN110177463A (zh) 2019-08-27
JP7383285B2 (ja) 2023-11-20
US20190314302A1 (en) 2019-10-17
EP3541185C0 (en) 2024-04-24
AU2017362328A1 (en) 2019-06-27
JP2019536778A (ja) 2019-12-19
US20250381155A1 (en) 2025-12-18
EP4385576A3 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
US20250381155A1 (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
ES2769000T3 (es) Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
Hall et al. The not so ‘mighty chondrion’: emergence of renal diseases due to mitochondrial dysfunction
Oh et al. Inhibition of pyruvate dehydrogenase kinase 4 ameliorates kidney ischemia-reperfusion injury by reducing succinate accumulation during ischemia and preserving mitochondrial function during reperfusion
Jalan et al. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy
AU2013259526B2 (en) New methods
Fu et al. Coordinated action of a gut–liver pathway drives alcohol detoxification and consumption
Kong et al. Effects of gestational isoflurane exposure on postnatal memory and learning in rats
TW201605434A (zh) 使用半胱胺及其衍生物治療粒腺體疾病
Gross Treatment of severe hyponatremia
US20070248689A1 (en) Copper lowering treatment of inflammatory and fibrotic diseases
ES2370790A1 (es) Uso de oxalacetato en el tratamiento de isquemia.
US20110065674A1 (en) Methods and compositions for improving cognitive function
HK40107155A (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
HK40006700A (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
HK40006700B (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
TWI737972B (zh) 心肌再灌流的方法及套组與減緩或減少心肌再灌流損傷的方法
AU2020210888A1 (en) Mitochondria-targeted isoketal/isolevuglandin scavengers
Wu et al. Beta-alanine promotes angiogenesis in laser-induced choroidal neovascularization mice models
Zhang Novel mechanism of 2DG mediated cancer treatment
US20210323949A1 (en) Compounds and methods for inhibition of multiple myeloma
AU2003231828B2 (en) Copper lowering treatment of inflammatory and fibrotic diseases
Sullivan New treatment options for cystic fibrosis
BR112016010338B1 (pt) Composição farmacêutica compreendendo um composto de diidrogenfosfato de 2-{[3,5-bis(trifluormetil)fenil]carbamoil}-4-clorofenila e uma ou mais bases de bronsted, kit compreendendo o dito composto e uso dos mesmos para tratar ou controlar edema
EA024164B1 (ru) Фармацевтическая композиция